Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG)-Reference-Cited by-同舟云学术

Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG)

Published:2020-06 Issue:3 Volume:20 Page:183-193
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Kittaneh Muaiad^ORCID,Badve Sunil,Caldera Humberto,Coleman Robert,Goetz Matthew P.,Mahtani Reshma,Mamounas Eleftherios,Kalinsky Kevin,Lower Elyse,Pegram Mark,Press Michael F.,Rugo Hope S.,Schwartzberg Lee,Traina Tiffany,Vogel Charles

Funder

Agendia, Inc

BioTheranostics, Inc

Myriad, Inc

Nanostring, Inc

Total Health Conferencing

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference42 articles.

1. Endocrine therapy and related issues in hormone receptor–positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG);Abraham;Breast Cancer Res Treat,2018

2. Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG)

3. A roundtable discussion of the Breast Cancer Therapy Expert Group (BCTEG): clinical developments and practice guidance on human epidermal growth factor receptor 2 (HER2) positive breast cancer;Abraham;Clin Breast Cancer,2020

4. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update;Krop;J Clin Oncol,2017

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ki67 assessment protocol as an integral biomarker for avoiding radiotherapy in the LUMINA breast cancer trial;Histopathology;2023-08-23

2. Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests;International Journal of Molecular Sciences;2022-11-06

3. A look at current and potential treatment approaches for hormone receptor‐positive, HER2‐negative early breast cancer;Cancer;2022-05-10

4. Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline;Current Oncology;2022-04-09

5. Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients?;Translational Oncology;2022-01